Stocks and Investing
Stocks and Investing
Tue, May 18, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, May 17, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Daina Graybosch Maintained (BOLT) at Buy with Decreased Target to $33 on, May 17th, 2021
Daina Graybosch of SVB Leerink, Maintained "Bolt Biotherapeutics, Inc." (BOLT) at Buy with Decreased Target from $37 to $33 on, May 17th, 2021.
Daina has made no other calls on BOLT in the last 4 months.
There are 3 other peers that have a rating on BOLT. Out of the 3 peers that are also analyzing BOLT, 0 agree with Daina's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Daina
- Matthew Harrison of "Morgan Stanley" Initiated at Buy and Held Target at $45 on, Tuesday, March 2nd, 2021
- Michael Schmidt of "Guggenheim" Initiated at Strong Buy and Held Target at $42 on, Tuesday, March 2nd, 2021
- Stephen Willey of "Stifel" Initiated at Strong Buy and Held Target at $40 on, Tuesday, March 2nd, 2021
Contributing Sources